Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers

Immunity

Volumn 40, Issue 5, 2014, Pages 657-668

  Falkowska, Emilia ^a,b   Le, Khoa M ^a   Ramos, Alejandra ^a   Doores, Katie J ^a,c   Lee, JeongHyun ^a   Blattner, Claudia ^a   Ramirez, Alejandro ^a   Derking, Ronald ^d   vanGils, Marit J ^d   Liang, Chi Hui ^a   Mcbride, Ryan ^a   von Bredow, Benjamin ^e   Shivatare, Sachin S ^f   Wu, Chung Yi ^f   Chan Hui, Po Ying ^g   Liu, Yan ^h   Feizi, Ten ^h   Zwick, Michael B ^a   Koff, Wayne C ⁱ   Seaman, Michael S ^j   Swiderek, Kristine ^g   Moore, John P ^k   Evans, David ^e   Paulson, James C ^a   Wong, Chi Huey ^f   Ward, Andrew B ^a   Wilson, Ian A ^a   Sanders, Rogier W ^d,k   Poignard, Pascal ^a   Burton, Dennis R ^a,b   more..

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c GUY S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f GENOMICS RESEARCH CENTER   (Taiwan)

^g Theraclone Sciences Inc   (United States)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^j BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^k WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCAN DERIVATIVE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PGT151 ANTIBODY; PGT152 ANTIBODY; PGT153 ANTIBODY; PGT154 ANTIBODY; PGT155 ANTIBODY; PGT156 ANTIBODY; PGT157 ANTIBODY; PGT158 ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ISOLATION; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; EPITOPE MAPPING; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN FAMILY; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS SPIKE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELL LINE; EPITOPES; HEK293 CELLS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; POLYSACCHARIDES;

EID: 84900517557     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2014.04.009     Document Type: Article

References (60)

1. Alpert M.D., Heyer L.N., Williams D.E.J., Harvey J.D., Greenough T., Allhorn M., Evans D.T. Articles of significant interest selected from this issue by the editors. J.Virol. 2012, 86:11955.
2. Barbas C.F., Bjorling E., Chiodi F., Dunlop N., Cababa D., Jones T.M., Zebedee S.L., Persson M.A.A., Nara P.L., Norrby E., Burton D.R. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. 1992, 89:9339-9343.
3. Barouch D.H., Whitney J.B., Moldt B., Klein F., Oliveira T.Y., Liu J., Stephenson K.E., Chang H.-W., Shekhar K., Gupta S., et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013, 503:224-228.
4. Blattner C., Lee J.H., Sliepen K., Derking R., Falkowska E., Torrents de la Peña A., Cupo A., Julien J.P., van Gils M., Lee P.M., et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 2014, 40. Published online April 24, 2014. 10.1016/j.immuni.2014.04.008.
5. Blixt O., Head S., Mondala T., Scanlan C., Huflejt M.E., Alvarez R., Bryan M.C., Fazio F., Calarese D., Stevens J., et al. Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc. Natl. Acad. Sci. USA 2004, 101:17033-17038.
6. Bonomelli C., Doores K.J., Dunlop D.C., Thaney V., Dwek R.A., Burton D.R., Crispin M., Scanlan C.N. The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS ONE 2011, 6:e23521.
7. Bontjer I., Melchers M., Eggink D., David K., Moore J.P., Berkhout B., Sanders R.W. Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution. J.Biol. Chem. 2010, 285:36456-36470.
8. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., Gruber G., Tauer C., Steindl F., Jungbauer A., et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 1994, 10:359-369.
9. Buchacher A., Predi R., Tauer C., Purtscher M., Gruber G., Heider R., Steindl F., Trkola A., Jungbauer A., Katinger H. Vaccines '92: Modern Approaches to New Vaccines Including Prevention of AIDS 1992, 191-194. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. F. Brown, R. Chanock, H.S. Ginsberg, R. Lerner (Eds.).
10. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027.
11. Burton D.R., Poignard P., Stanfield R.L., Wilson I.A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012, 337:183-186.
12. Chakrabarti B.K., Pancera M., Phogat S., O'Dell S., McKee K., Guenaga J., Robinson J., Mascola J., Wyatt R.T. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies. AIDS Res. Hum. Retroviruses 2011, 27:877-887.
13. Doores K.J., Burton D.R. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J.Virol. 2010, 84:10510-10521.
14. Doria-Rose N.A., Georgiev I., O'Dell S., Chuang G.-Y., Staupe R.P., McLellan J.S., Gorman J., Pancera M., Bonsignori M., Haynes B.F., et al. A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J.Virol. 2012, 86:8319-8323.
15. Falkowska E., Ramos A., Feng Y., Zhou T., Moquin S., Walker L.M., Wu X., Seaman M.S., Wrin T., Kwong P.D., et al. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J.Virol. 2012, 86:4394-4403.
16. Feizi T., Chai W. Oligosaccharide microarrays to decipher the glyco code. Nat. Rev. Mol. Cell Biol. 2004, 5:582-588.
17. Ferguson A.L., Falkowska E., Walker L.M., Seaman M.S., Burton D.R., Chakraborty A.K. Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data. PLoS ONE 2013, 8:e80562.
18. Go E.P., Irungu J., Zhang Y., Dalpathado D.S., Liao H.-X., Sutherland L.L., Alam S.M., Haynes B.F., Desaire H. Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J.Proteome Res. 2008, 7:1660-1674.
19. Go E.P., Chang Q., Liao H.-X., Sutherland L.L., Alam S.M., Haynes B.F., Desaire H. Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. J.Proteome Res. 2009, 8:4231-4242.
20. Guttman M., Kahn M., Garcia N.K., Hu S.L., Lee K.K. A functional interaction between gp41 and gp120 is observed for monomeric but not oligomeric, uncleaved HIV-1 Env gp140. J.Virol. 2013, 87:11462-11475.
21. Huang J., Ofek G., Laub L., Louder M.K., Doria-Rose N.A., Longo N.S., Imamichi H., Bailer R.T., Chakrabarti B., Sharma S.K., et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012, 491:406-412.
22. Jardine J., Julien J.-P., Menis S., Ota T., Kalyuzhniy O., McGuire A., Sok D., Huang P.-S., MacPherson S., Jones M., et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013, 340:711-716.
23. Julien J.-P., Cupo A., Sok D., Stanfield R.L., Lyumkis D., Deller M.C., Klasse P.J., Burton D.R., Sanders R.W., Moore J.P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1477-1483. 10.1126/science.1245625.
24. Julien J.-P., Sok D., Khayat R., Lee J.H., Doores K.J., Walker L.M., Ramos A., Diwanji D.C., Pejchal R., Cupo A., et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 2013, 9:e1003342.
25. Klein F., Gaebler C., Mouquet H., Sather D.N., Lehmann C., Scheid J.F., Kraft Z., Liu Y., Pietzsch J., Hurley A., et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J.Exp. Med. 2012, 209:1469-1479.
26. Klein F., Halper-Stromberg A., Horwitz J.A., Gruell H., Scheid J.F., Bournazos S., Mouquet H., Spatz L.A., Diskin R., Abadir A., et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012, 492:118-122.
27. Klein F., Mouquet H., Dosenovic P., Scheid J.F., Scharf L., Nussenzweig M.C. Antibodies in HIV-1 vaccine development and therapy. Science 2013, 341:1199-1204.
28. Kong L., Giang E., Nieusma T., Kadam R.U., Cogburn K.E., Hua Y., Dai X., Stanfield R.L., Burton D.R., Ward A.B., et al. Hepatitis C virus E2 envelope gylocoprotein core structure. Science 2013, 342:1090-1094.
29. Kong L., Lee J.H., Doores K.J., Murin C.D., Julien J.-P., McBride R., Liu Y., Marozsan A., Cupo A., Klasse P.J., et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 2013, 20:796-803.
30. Kulp D.W., Schief W.R. Advances in structure-based vaccine design. Curr. Opin. Virol. 2013, 3:322-331.
31. Kwong P.D., Mascola J.R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012, 37:412-425.
32. Lee J.E., Fusco M.L., Hessell A.J., Oswald W.B., Burton D.R., Saphire E.O. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 2008, 454:177-182.
33. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J.Virol. 2005, 79:10108-10125.
34. Li Y., O'Dell S., Wilson R., Wu X., Schmidt S.D., Hogerkorp C.-M., Louder M.K., Longo N.S., Poulsen C., Guenaga J., et al. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. J.Virol. 2012, 86:11231-11241.
35. Liang C.-H., Wang S.-K., Lin C.-W., Wang C.-C., Wong C.-H., Wu C.-Y. Effects of neighboring glycans on antibody-carbohydrate interaction. Angew. Chem. Int. Ed. Engl. 2011, 50:1608-1612.
36. Liu J., Bartesaghi A., Borgnia M.J., Sapiro G., Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008, 455:109-113.
37. Lyumkis D., Julien J.-P., de Val N., Cupo A., Potter C.S., Klasse P.J., Burton D.R., Sanders R.W., Moore J.P., Carragher B., et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1484-1490. 10.1126/science.1245627.
38. Mascola J.R., Haynes B.F. HIV-1 neutralizing antibodies: Understanding nature's pathways. Immunol. Rev. 2013, 254:225-244.
39. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.-P., Khayat R., Louder R., Pejchal R., Sastry M., Dai K., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
40. McLellan J.S., Chen M., Joyce M.G., Sastry M., Stewart-Jones G.B.E., Yang Y., Zhang B., Chen L., Srivatsan S., Zheng A., et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013, 342:592-598.
41. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Rüker F., Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J.Virol. 1993, 67:6642-6647.
42. Pancera M., Wyatt R. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 2005, 332:145-156.
43. Pantophlet R., Ollmann Saphire E., Poignard P., Parren P.W.H.I., Wilson I.A., Burton D.R. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J.Virol. 2003, 77:642-658.
44. Pejchal R., Doores K.J., Walker L.M., Khayat R., Huang P.-S., Wang S.-K., Stanfield R.L., Julien J.-P., Ramos A., Crispin M., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334:1097-1103.
45. Ringe R.P., Sanders R.W., Yasmeen A., Kim H.J., Lee J.H., Cupo A., Korzun J., Derking R., van Montfort T., Julien J.-P., et al. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc. Natl. Acad. Sci. USA 2013, 110:18256-18261.
46. Sanders R.W., Derking R., Cupo A., Julien J.-P., Yasmeen A., de Val N., Kim H.J., Blattner C., de la Peña A.T., Korzun J., et al. A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013, 9:e1003618.
47. Scheid J.F., Mouquet H., Feldhahn N., Seaman M.S., Velinzon K., Pietzsch J., Ott R.G., Anthony R.M., Zebroski H., Hurley A., et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458:636-640.
48. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Oliveira T.Y.K., Pietzsch J., Fenyo D., Abadir A., Velinzon K., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333:1633-1637.
49. Shingai M., Nishimura Y., Klein F., Mouquet H., Donau O.K., Plishka R., Buckler-White A., Seaman M., Piatak M., Lifson J.D., et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 2013, 503:277-280.
50. Shivatare S.S., Chang S.-H., Tsai T.-I., Ren C.-T., Chuang H.-Y., Hsu L., Lin C.-W., Li S.-T., Wu C.-Y., Wong C.-H. Efficient convergent synthesis of bi-, tri-, and tetra-antennary complex type N-glycans and their HIV-1 antigenicity. J.Am. Chem. Soc. 2013, 135:15382-15391.
51. Simek M.D., Rida W., Priddy F.H., Pung P., Carrow E., Laufer D.S., Lehrman J.K., Boaz M., Tarragona-Fiol T., Miiro G., et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J.Virol. 2009, 83:7337-7348.
52. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J.Virol. 1996, 70:1100-1108.
53. Walker L.M., Phogat S.K., Chan-Hui P.-Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289. Protocol G Principal Investigators.
54. Walker L.M., Simek M.D., Priddy F., Gach J.S., Wagner D., Zwick M.B., Phogat S.K., Poignard P., Burton D.R. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 2010, 6:e1001028.
55. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.-P., Wang S.-K., Ramos A., Chan-Hui P.-Y., Moyle M., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470. Protocol G Principal Investigators.
56. Wu X., Yang Z.-Y., Li Y., Hogerkorp C.-M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
57. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., Chen X., Longo N.S., Louder M., McKee K., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602. NISC Comparative Sequencing Program.
58. Zhang M.-Y., Yuan T., Li J., Rosa Borges A., Watkins J.D., Guenaga J., Yang Z., Wang Y., Wilson R., Li Y., et al. Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41. PLoS ONE 2012, 7:e44241.
59. Zhou T., Georgiev I., Wu X., Yang Z.-Y., Dai K., Finzi A., Kwon Y.D., Scheid J.F., Shi W., Xu L., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811-817.
60. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J.Virol. 2001, 75:10892-10905.